Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2626 to 2640 of 9035 results

  1. Technologies for the rapid diagnosis of endometriosis: early use assessment

    In development Reference number: GID-HTE10082 Expected publication date:  08 October 2026

    In development

  2. Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

    In development Reference number: GID-TA11819 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  3. Palbociclib with anti-HER2 and endocrine therapies for maintenance treatment of hormone-receptor positive HER2-positive metastatic breast cancer [ID6251]

    Awaiting development Reference number: GID-TA11273 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment

    In development Reference number: GID-HTE10011 Expected publication date: TBC

    In development

  5. Technologies to improve the detection of endometrial cancer

    Topic prioritisation

    Topic prioritisation

  6. Ex-situ machine perfusion devices for lung transplants

    In development Reference number: GID-HTE10084 Expected publication date:  21 October 2026

    In development

  7. Software for electroencephalogram (EEG) interpretation to support diagnosing epilepsy

    In development Reference number: GID-HTE10086 Expected publication date:  15 September 2026

    In development

  8. Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6413]

    In development Reference number: GID-TA11488 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Familial Breast Cancer: initial assessment and genetic testing (update)

    In development Reference number: GID-NG10438 Expected publication date:  22 April 2027

    NICE guideline
    In development

  11. Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]

    In development Reference number: GID-TA11052 Expected publication date:  17 February 2027

    Technology appraisal guidance
    In development

  12. Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]

    In development Reference number: GID-TA11743 Expected publication date:  13 May 2027

    Technology appraisal guidance
    In development

  13. Digital platforms to support rehabilitation before and after primary elective hip or knee replacement surgery

    In development Reference number: GID-HTE10069 Expected publication date:  13 October 2026

    In development

  14. Ruxolitinib for treating moderate atopic dermatitis ID6602

    In development Reference number: GID-TA11809 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer ID6573

    In development Reference number: GID-TA11755 Expected publication date: TBC

    Technology appraisal guidance
    In development